Literature DB >> 32533986

Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.

Takayuki Yamada1, Mako Wakabayashi2, Takahiro Yamaji3, Nitin Chopra4, Takahisa Mikami4, Hirotaka Miyashita4, Satoshi Miyashita4.   

Abstract

BACKGROUND: Since December 2019, coronavirus 2019 (COVID-19) has spread worldwide. Identifying poor prognostic factors is helpful for risk stratification. In this meta-analysis, we investigated the association between severe COVID-19 and a change in white blood cell (WBC) count, an elevation of C-reactive protein (CRP), and fever. Moreover, we aimed to evaluate the diagnostic accuracy of leukocytosis and an elevation of CRP.
METHODS: We performed a systematic search of PubMed, EMBASE, Scopus, and the Cochrane Library through April 20th, 2020. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A sensitivity analysis was conducted according to the study size (>200 or <200) and median age (>55 or <55). Meta-regression analyses were conducted to examine possible sources of heterogeneity. We calculated the diagnostic accuracy of leukocytosis and CRP.
RESULTS: Eighteen studies with 3278 patients were selected. Fever, leukocytosis, and elevated CRP were associated with poor outcomes (OR (95% CI) 1.63 (1.06-2.51), 4.51 (2.53-8.04), and 11.97 (4.97-28.8), respectively). Leukopenia was associated with a better prognosis (OR 0.56, 95% CI 0.40-0.78). Sensitivity analyses showed similar tendencies. Meta-regression analysis for leukocytosis indicated that age, dyspnea, and hypertension contributed to heterogeneity. The pooled area under the leukocytosis and CRP curves were 0.70 (0.64-0.76) and 0.89 (0.80-0.99), respectively.
CONCLUSION: In patients with COVID-19, fever, leukocytosis, and an elevated CRP were associated with severe outcomes. Leukocytosis and CRP on arrival may predict poor outcomes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; CRP; Critically ill; Fever; Luekocytosis; Meta-analysis; Prediction; White blood cell

Mesh:

Substances:

Year:  2020        PMID: 32533986     DOI: 10.1016/j.cca.2020.06.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  Clinical Features and Outcome of Stroke with COVID-19. COVID-19 Stroke Study Group (CSSG), India.

Authors:  Rohit Bhatia; M V Padma Srivastava; P N Sylaja; Snigdha Komakula; Ashish Upadhyay; Vibhor Pardasani; Thomas Iype; Rajsrinivas Parthasarathy; Rajshekhar Reddy; Suman Kushwaha; Jayanta Roy; P Satish; Anjan Trikha; Naveet Wig; Lalit Dhar; Deepti Vibha; Venugopalan Y Vishnu; Awadh Kishore Pandit; Anu Gupta; A Elavarasi; Ayush Agarwal; Vipul Gupta; Rakesh K Singh; Harsh Oza; Hiral Halani; Dileep Ramachandran; Githin B George; Praveen Panicker; M K Suresh; S Kumaravelu; Dheeraj Khurana; Srijithesh P Rajendran; Vijaya Pamidimukkala; Salil Gupta; Jeyaraj D Pandian; Debashish Chowdhury; Nirendra K Rai; Arvind Sharma; Vivek K Nambiar
Journal:  Ann Indian Acad Neurol       Date:  2021-08-30       Impact factor: 1.383

2.  Prognostic value of biochemical parameters among severe COVID-19 patients admitted to an intensive care unit of a tertiary hospital in South Africa.

Authors:  Annalise E Zemlin; Brian Allwood; Rajiv T Erasmus; Tandi E Matsha; Zivanai C Chapanduka; Thumeka P Jalavu; Vera Ngah; Lovemore N Sigwadhi; Coenraad F Koegelenberg; Elvis Irusen; Usha Lalla; Anteneh Yalew; Nicola Baines; Jacques L Tamuzi; Anne K Barasa; Valerie Kemunto Magutu; Caroline Njeru; Angela Amayo; Marianne Wanjiru Mureithi; Mary Mungania; Musa Sono-Setati; Alimuddin Zumla; Peter S Nyasulu
Journal:  IJID Reg       Date:  2022-01-23

3.  C-reactive protein as an effector molecule in Covid-19 pathogenesis.

Authors:  Jesús A Mosquera-Sulbaran; Adriana Pedreañez; Yenddy Carrero; Diana Callejas
Journal:  Rev Med Virol       Date:  2021-02-17       Impact factor: 11.043

4.  Leukemoid Reaction in a Patient With Severe COVID-19 Infection.

Authors:  Kidist Tarekegn; Ana Colon Ramos; Harry G Sequeira Gross; Ming Yu; Ilmana Fulger
Journal:  Cureus       Date:  2021-02-27

5.  Hyponatremia is associated with poor outcome in COVID-19.

Authors:  Hugo De Carvalho; Thibault Letellier; Matilde Karakachoff; Geoffrey Desvaux; Hélène Caillon; Emmanuelle Papuchon; Maxime Bentoumi-Loaec; Nesrine Benaouicha; Emmanuel Canet; Guillaume Chapelet; Paul Le Turnier; Emmanuel Montassier; Armine Rouhani; Nicolas Goffinet; Lucile Figueres
Journal:  J Nephrol       Date:  2021-04-07       Impact factor: 3.902

6.  Monocyte distribution width as a novel sepsis indicator in COVID-19 patients.

Authors:  Laila Alsuwaidi; Saba Al Heialy; Nahid Shaikh; Firas Al Najjar; Rania Seliem; Aaron Han; Mahmood Hachim
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

7.  Hyperleukocytosis and Pseudohyperkalemia in a Patient With Severe SARS-COVID 19 Unmasks Chronic Lymphocytic Leukemia.

Authors:  Sasmith R Menakuru; Adelina Priscu; Amir Beirat; Vijaypal S Dhillon; Ahmed Salih; Joseph Emran
Journal:  Cureus       Date:  2021-12-30

8.  Using decision tree algorithms for estimating ICU admission of COVID-19 patients.

Authors:  Mostafa Shanbehzadeh; Raoof Nopour; Hadi Kazemi-Arpanahi
Journal:  Inform Med Unlocked       Date:  2022-03-18

9.  Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients.

Authors:  Ayad M Ali; Hassan M Rostam; Mohammed H Fatah; Chalak M Noori; Kameran M Ali; Hassan M Tawfeeq
Journal:  Immun Inflamm Dis       Date:  2021-12-22

10.  Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis.

Authors:  Szabolcs Kiss; Noémi Gede; Péter Hegyi; Dávid Németh; Mária Földi; Fanni Dembrovszky; Bettina Nagy; Márk Félix Juhász; Klementina Ocskay; Noémi Zádori; Zsolt Molnár; Andrea Párniczky; Péter Jenő Hegyi; Zsolt Szakács; Gabriella Pár; Bálint Erőss; Hussain Alizadeh
Journal:  Med Microbiol Immunol       Date:  2020-11-21       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.